Decipher is now part of Veracyte!     Learn More
Decipher is now part of Veracyte!     Learn More
Skip to content
PRESS RELEASES

PRESS RELEASES

Date Title and Summary Additional Formats
Toggle Summary Veracyte Announces New General Manager Structure to Advance Global Expansion
John Hanna appointed GM , endocrinology, breast cancer and lymphoma; Morten Frost to join company as GM , pulmonology SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Nov. 17, 2020-- Veracyte (Nasdaq: VCYT) today announced a new general manager-based structure to advance the company’s growing roster
View HTML
Toggle Summary Prosigna Breast Cancer Assay Now Approved for Reimbursement in Germany
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Nov. 5, 2020-- Veracyte, Inc. (Nasdaq: VCYT), a pioneering genomic diagnostics company, announced that the Federal Joint Committee (G-BA) has approved its Prosigna® Breast Cancer Gene Signature Assay. The G-BA decision to reimburse the Prosigna test
View HTML
Toggle Summary Veracyte Announces Third Quarter 2020 Financial Results
Revenue of $31.1 Million ; Product and Testing Revenue Increased 79% Over Second Quarter of 2020 Achieved Key Reimbursement Milestones Conference Call and Webcast Today at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Nov. 2, 2020-- Veracyte, Inc .
View HTML
Toggle Summary Veracyte Announces New Data Published in Journal of Clinical Oncology Suggest the Prosigna Breast Cancer Test’s Genomic Underpinning Drives Prognostic Performance
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Oct. 30, 2020-- Veracyte, Inc ., (Nasdaq: VCYT) announced today that findings from the first study evaluating the molecular drivers underlying multiple prognostic genomic breast cancer tests were published in the Journal of Clinical Oncology (JCO).
View HTML
Toggle Summary Veracyte Announces Publication of Manuscript Describing Scientific Rigor Behind Next-Generation Percepta Genomic Sequencing Classifier
RNA sequencing and novel machine learning algorithms generate a test that improves lung cancer diagnosis using brushings from the main lung airway SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Oct. 22, 2020-- Veracyte, Inc . (Nasdaq: VCYT) today announced the publication of a manuscript detailing
View HTML
Toggle Summary Veracyte Announces New Data Reinforcing Foundational Technology of Nasal Swab Test for Early Lung Cancer Detection Presented at CHEST Annual Meeting 2020
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Oct. 19, 2020-- Veracyte, Inc ., (Nasdaq: VCYT) today announced that new data presented at the CHEST Annual Meeting 2020 show that a genomic smoking index developed for use on samples obtained from the main lung airway can also be detected in nasal
View HTML
Toggle Summary Veracyte Announces Two Presentations to Be Shared at CHEST Annual Meeting 2020
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Oct. 14, 2020-- Veracyte, Inc. (Nasdaq: VCYT) announced today that an oral presentation will be given at the CHEST Annual Meeting 2020 reinforcing the foundational technology behind its noninvasive nasal swab test to identify lung cancer risk in
View HTML
Toggle Summary Veracyte to Release Third Quarter 2020 Financial Results on November 2, 2020
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Oct. 7, 2020-- Veracyte, Inc . (Nasdaq: VCYT) announced today that it will release its financial results for the third quarter of 2020 after the close of market on Monday, November 2, 2020 . Company management will host a conference call and webcast to
View HTML
Toggle Summary Veracyte Receives ADLT Status for Envisia Genomic Classifier From Centers for Medicare and Medicaid Services
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Sep. 24, 2020-- Veracyte, Inc . (Nasdaq: VCYT) announced today that the Centers for Medicare and Medicaid Services (CMS) has approved new Advanced Diagnostic Laboratory Test (ADLT) status for the Envisia ® Genomic Classifier.
View HTML
Toggle Summary Veracyte to Present at Two Investor Conferences
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Sep. 15, 2020-- Veracyte, Inc . (Nasdaq: VCYT), a global genomic diagnostics company, announced today that Bonnie H. Anderson , chairman and chief executive officer, is scheduled to participate in two virtual investor conferences this week: 2020 Cantor
View HTML